Medicilon is listed in the 2022 China Biopharmaceutical Industry Value List

저자：medicilon   업로드：2022-08-15  조회수：

On August 4, 2022, the 6th China Bio-Pharma Partnering Forum 2022 and the 2022 China Biomedical Industry Value List Award Ceremony was held, Shanghai Medicilon Inc. was on the list of the "Top 20 Most Influential CXO Enterprise."

이전：Medicilon was awarded the Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022

다음에：Medicilon and BravoBio have reached a strategic collaboration on innovative vaccine IND R&D services